Voices from the Analytical Front Line: Bingchuan Wei on Chromatography in 2026

LCGC International spoke with Bingchuan Wei, senior principal scientist at Genentech Inc., about the key developments he expects to influence chromatography in 2026. With experience in analytical and CMC development across a wide range of therapeutic modalities, Wei shares his perspective on how advanced analytical technologies and evolving industry needs will shape the year ahead. Listen to his insights below:

Bingchuan Wei is a senior principal scientist from Genentech Inc, a member of Roche Group. He is a scientific leader with nearly 15 years of experience in the analytical and CMC development of different modalities of therapeutics including small molecules, oligonucleotides, peptides, monoclonal antibodies, antibody-drug conjugates, and cell therapies. His research focuses on developing and leveraging advanced analytical technologies in drug development, understanding the structural-functional relationship of therapeutics, and fostering entrepreneurial spirit in the biopharmaceutical industry. He holds a Ph.D in analytical chemistry from Purdue University, a master of business administration from The Pennsylvania State University, and a B.S. in chemistry and mathematics from Peking University.

For more viewpoints, please click the links below:

Voices from the Analytical Front Line: Thomas Letzel on Chromatography in 2026

Voices from the Analytical Front Line: Brett Paull on Chromatography in 2026

Voices from the Analytical Front Line: Dave Bell on Chromatography in 2026

Voices from the Analytical Front Line: Tony Edge on Chromatography in 2026